Lupin receives US FDA Establishment Inspection Report for Somerset facility

Lupin has announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its manufacturing facility in Somerset, New Jersey. The report follows an inspection conducted from 27 January to 31 January 2025.

Nilesh Gupta, Managing Director of Lupin, stated, “We are very pleased to have received the EIR for our Somerset facility. This milestone underscores our commitment to upholding the highest standards of quality and compliance, solidifying our position as a leading pharmaceutical manufacturer.”

Related Posts

Telangana HM orders action against misleading pharma ads, sale of substandard drugs

Hyderabad: In a stern message to the pharmaceutical industry, Telangana Health Minister Damodar Rajanarsimha has ordered the Drug Control Authority (DCA) to take stringent action against companies and individuals involved…

LOC issued against man who sold fake Ozempic worth Rs 180 crore to US firm

New Delhi:  A lookout circular (LOC) has been issued against the man who allegedly sold fake Ozempic worth Rs 180 crore to a United States-based firm, officers have said. According…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Telangana HM orders action against misleading pharma ads, sale of substandard drugs

Telangana HM orders action against misleading pharma ads, sale of substandard drugs

Aurobindo Pharma clarifies, reports of Zentiva buyout ‘premature’, no binding agreement yet

Aurobindo Pharma clarifies, reports of Zentiva buyout ‘premature’, no binding agreement yet

AIIMS study finds catheter infections in hospital widespread across India

AIIMS study finds catheter infections in hospital widespread across India

MNCs seek restart of refurbished medical device imports

MNCs seek restart of refurbished medical device imports